Crohn’s disease: SAR441566 study

What is this study about?

This is a Phase 2 study examining the efficacy and safety of a new drug called SAR441566 in adults with moderate to severe Crohn’s disease. Various dosages of SAR441566 are compared to a placebo (sham drug) to determine which works best.

Who can participate?

Adults diagnosed with moderate to severe Crohn’s disease.

How long does the study last?

Up to 59 weeks, consisting of:

  • Screening phase (approx. 4 weeks)
  • Main treatment phase (52 weeks)
  • Follow-up (2 weeks after the end of treatment)

What happens during the study?

The main study includes 12 weeks of induction treatment and 40 weeks of maintenance phase.
Some participants may participate in an open-label treatment phase (up to 40 weeks) in which everyone receives the study drug.

Sanofi
ClinicalTrials.gov ID: NCT06637631

Register now without obligation

CED Kontaktform vormerken